Half-Year 2022 Financial and Clinical Trials Update

Actemra/RoActemra Global sales CHFbn CER growth -10% Regional sales CER growth US -7% 1.8 1.5 1.2 0.9 0.6 0.3 0.0 HY 19 HY 20 HY 21 HY 22 HY 2022 sales of CHF 1,455m Europe -3% Japan +4% International -37% • US: Actemra SC share in RA keeps increasing; Limited COVID-19 sales in Q2 as hospitalizations have come down significantly • . Roche EU: Market leadership in 1L RA monotherapy maintained; Limited COVID-19 sales in Q2 as hospitalizations have come down significantly International: Limited COVID-19 sales in Q2 as hospitalizations have come down significantly CER=Constant Exchange Rates 174

View entire presentation